These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2515722)

  • 1. Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():165-9. PubMed ID: 2515722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Rinne UK
    Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1991; 136():95-8. PubMed ID: 1801545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline in the treatment of Parkinson's disease.
    Heinonen EH; Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():103-11. PubMed ID: 2515715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The dopamine agonist, lisuride, in the therapy of Parkinson disease].
    Madeja UD
    Acta Histochem Suppl; 1992; 42():25-31. PubMed ID: 1584973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deprenyl (selegiline) in combination treatment of Parkinson's disease.
    Gerstenbrand F; Ransmayr G; Poewe W
    Acta Neurol Scand Suppl; 1983; 95():123-6. PubMed ID: 6428144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of lisuride in advanced Parkinson's disease.
    Meneghetti G; Bracco F; Giometto B; Ferla S; Schergna E
    Eur Neurol; 1986; 25(1):74-80. PubMed ID: 3510126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy].
    Rinne UK
    Nervenarzt; 1999 Jan; 70 Suppl 1():S19-25. PubMed ID: 10087526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical therapeutics: advances in the management of Parkinson's disease.
    Adam AM
    East Afr Med J; 1985 Feb; 62(2):143-6. PubMed ID: 3930202
    [No Abstract]   [Full Text] [Related]  

  • 13. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
    Heinonen EH; Rinne UK; Tuominen J
    Acta Neurol Scand Suppl; 1989; 126():113-8. PubMed ID: 2515716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.
    Lieberman A; Goldstein M; Neophytides A; Kupersmith M; Leibowitz M; Zasorin N; Walker R; Kleinberg D
    Neurology; 1981 Aug; 31(8):961-5. PubMed ID: 7022259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
    Stocchi F; Ruggieri S; Antonini A; Baronti F; Brughitta G; Bellantuono P; Bravi D; Agnoli A
    J Neural Transm Suppl; 1988; 27():27-33. PubMed ID: 3165437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
    Sivertsen B; Dupont E; Mikkelsen B; Mogensen P; Rasmussen C; Boesen F; Heinonen E
    Acta Neurol Scand Suppl; 1989; 126():147-52. PubMed ID: 2515720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Goodgold A; Pact V; Walker R
    N Y State J Med; 1981 Nov; 81(12):1751-5. PubMed ID: 6949052
    [No Abstract]   [Full Text] [Related]  

  • 19. Selegiline in the treatment of Parkinson's disease--long term experience.
    Yahr MD; Elizan TS; Moros D
    Acta Neurol Scand Suppl; 1989; 126():157-61. PubMed ID: 2515721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.